Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-02-14
2006-02-14
Minnifield, Nita (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007230, C436S811000, C436S536000, C530S300000, C530S350000
Reexamination Certificate
active
06998242
ABSTRACT:
A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10−7M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4444879 (1984-04-01), Foster et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5366859 (1994-11-01), Miyoshi et al.
patent: 5374529 (1994-12-01), Caterson et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5427954 (1995-06-01), Sandy et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5578569 (1996-11-01), Tam
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5830850 (1998-11-01), Gelb et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6015938 (2000-01-01), Boyle
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6046033 (2000-04-01), Goto
patent: 0 514 130 (1992-11-01), None
patent: 0 727 211 (1996-08-01), None
patent: 0 784 093 (1997-07-01), None
patent: 0784093 (1997-07-01), None
patent: 0 816 380 (1998-01-01), None
patent: 0816380 (1998-01-01), None
patent: 330400 (1999-05-01), None
patent: 96/26217 (1996-08-01), None
patent: 96/28546 (1996-09-01), None
patent: 97/00317 (1997-01-01), None
patent: 97/00318 (1997-01-01), None
patent: 97/23614 (1997-07-01), None
patent: 98/07840 (1998-02-01), None
Simonet, WS et al, Cell, vol. 89, pp. 309-319, Apr. 18, 1997, Osteoprotegerin: A Novel secreted protein involved in the regulation of bone density.
Wong, BR et al, The Journal of Biological Chemistry, vol. 272, No. 40, Oct. 3, 1997, pp. 25190-25194, TRANCE is a NOvel ligand of the Tumor Necrosis Factor Receptor Family that Activates c-Jun N-terminal Kinase in T-cells.
Andersson, Karl et al, Journal of Molecular recognition, 1999, vol. 12, pp. 310-315, Exploring buffer space for molecular interactions.
Yasuda, H et al, Endocrinology, vol. 139(3), 1998, pp. 1329-1337, Identity of osteoclastogenesis inhibitory factor (OCIF) and Osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Simonet, WS et al, Cell, vol. 89, pp. 309-319, Apr. 18, 1997, Osteoprotegerin: A novel secreted protein involved in the regulation of bone density.
Emery, John G et al, The Journal of Biological Chemistry, vol. 273(23), Jun. 5, apges 14363-14367, 1998.
Morinaga, T et al,European J. of Biochemistry, vol. 254, pp. 685-691, 1998, Cloning and characterization of the gene encoding human osteoprotegrin/osteoclastogenesis-inhibiitory factor.
Yasuda, H et al, Endocrinology, vol. 159(3), pp. 1329-1337, 1998, Identity of osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits Osteoclastogenesis in vitro.
Min, H et al, J. Exp. Med. vol. 192(4), Aug. 2000, pp. 463-474, Osteoprotegerin Reverses Osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Yasuda, H et al, PNAS (USA), vol. 95, Mar. 1998, pp. 3597-3602, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogeneiss-inhibitory factor and is identical to TRANCE/RANKL.
Reddi, AH, Cell, vol. 89, pp. 159-161, Apr. 18, 1997, Minireview: Bone Morphogenesis and Modeling: Soluble Signals Sculpt Osteosomes in the solid state.
Lacey, DL et al, Cell, vol. 93, pp. 165-176, Apr. 17, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Morabito, Nunziata et al, Journal of Bone and Mineral Research, May 2004, vol. 19(5), pp. 722+ (8 pages plus figures), Osteoprotegerin and RANL in the pathogenesis of thalassemia induced osteoporosis: New pieces of the puzzle.
Adams et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project”,Science, vol. 252, No. 21, pp. 1651-1656 (1991).
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function”,Nature, vol. 390, pp. 175-179 (1997).
Chambers et al., “Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2btsA58 transgenic mouse”,Proceed. of the National Acad. of Sciences of USA, vol. 90, pp. 5578-5582 (1993).
Chenu et al., “Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cells”,Proceed. of the National Acad. of Sciences of USA, vol. 85, pp. 5683-5687 (1998).
Fawthrop et al., “The Effect of Transforming Growth Factor β on the Plasminogen Activator Activity of Normal Human Osteoblast-like Cells and a Human Osteosarcoma Cell Line MG-63”,J. Bone and Mineral Res., vol. 7, No. 12, pp. 1363-1371 (1992).
Fenton et al., “Long-Term Culture of Disaggregated Rat Osteoclasts: Inhibition of Bone Resorption and Reduction of Osteoclast-Like Cell Number of Calcitonin and PTHrP[107-139]”,J. Cellular Phys., vol. 155, pp. 1-7 (1993).
George et al.,Macromolecular Sequencing and Synthesis, New York, pp. 127-149 (1998).
Goodwin et al., “Molecular cloning and expression of the type 1 and type 2 receptors for tumor necrosis factor”, Database EMROD, EMBL Databases, Accession No.: M59378 (1991).
Gowen et al., “Preferential Inhibition of Cytokine-Stimulated Bone Resorption by Recombinant Interferon Gamma”,Journal of Bone and Mineral Research, vol. 1, No. 5, pp. 469-474 (1986).
Hattersley et al., “Human Macrophage Colony-Stimulating Factor Inhibits Bone Resorption by Osteoclasts Disaggregated from Rat Bone”,Journal of Cellular Physiology, vol. 137, No. 1, pp. 199-203 (1998).
International Search Report for PCT/JP98/01728.
Kaji et al., “Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone”,Journal of Cellular Physiology, vol. 172, No. 1, pp. 55-62 (1997).
Kasono et al., “Inhibitory effect of Interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture”,Bone and Mineral, vol. 21, pp. 179-188 (1993).
Kukita et al., “Osteoinductive factor inhibits formation of human osteoclast-like cells”,Proc. Natl. Acad. Sci. USA, vol. 87, pp. 3023-3026 (1990).
Lewis et al., “Cloning and expression of cDNAS for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific”,Proc. Natl. Aca. Sci. USA, vol. 88, pp. 2830-2834 (1991).
Reddi, “Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state”,CELL, vol. 89, pp. 159-161 (1997).
Rieger et al.,Glossary of Genetics and Cytogenetics, Springer-Verlag, Berlin Heidlberg New York, pp. 17.0 (1976).
Simonet et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density”,CELL, vol. 89, pp. 309-319 (1997).
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death”,CELL, vol. 76, pp. 959-962 (1994).
Suda et al., “Modulation of Osteoclast Differentiation by Local Factors”,Bone, vol. 117, 2ndSupplement, pp. 87S-91S (1995).
Takada et al., “A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells”,Bone and Mineral, vol. 17, pp. 347-359 (1992).
Tsuda et al., “Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis”,Biochem. and Biophys. Research Commun., vol. 234, pp. 137-142 (1997).
Watanabe e
Goto Masaaki
Higashio Kaoji
Kobayashi Fumie
Tsuda Eisuke
Washida Naohiro
Arnold & Porter LLP
Minnifield Nita
Portner Ginny Allen
Sankyo Co. Ltd.
LandOfFree
Method of diagnosing metabolic bone diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of diagnosing metabolic bone diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing metabolic bone diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638114